Low-dose sclerotherapy with lauromacrogol in the treatment of infantile hemangiomas: A retrospective analysis of 368 cases

Abstract

BackgroundIntralesional injection of lauromacrogol has proven to be an efficient treatment method for infantile hemangioma. This study aims to explore a novel injection therapy and evaluate its efficacy and complications.MethodsThe medical records of 368 children with infantile hemangioma who received a lauromacrogol injection from January 2021 to April 2022 were retrospectively analyzed. All patients were reviewed every 4 weeks, and their condition was assessed according to symptoms and medical records. The patient’s age, lesion type, location, size and thickness, lesion photographs, ultrasound, and complications were recorded.ResultsAmong the 368 infants who accept sclerotherapy with lauromacrogol, 226(61.4%)achieved excellent regression. In total, 108(29.4%)cases achieved good regression. 24(6.5%)achieved complete moderate regression. 10(2.7%)achieved poor regression. The reported incidence of adverse events was 4.9% and severe complications were not observed. Before and after three courses of treatment, the median vascular endothelial growth factor levels were 104.12 pg/ml and 28.982 pg/ml. There was a significant difference between the two groups (P=0.0043).ConclusionsThe results showed that this novel injection therapy a safe and effective treatment method. The therapy accelerated the regression of infantile hemangiomas without serious complications.

Efficacy and preliminary dose studies of ultrasound-guided sclerotherapy with lauromacrogol for the treatment of implanted hepatic tumors in rabbits

“…Lauromacrogol is mainly used for sclerotherapy of esophagogastric varices and lower extremity varicose veins. Later, it was clinically used as a sclerosing agent in some diseases and had an excellent effect, such as Ultrasoundguided polidocanol for symptomatic giant hepatic cystr syasound-guided sclerosant injection for cesarean scar pregnancy; low-dose sclerotherapy with lauromacrogol in the treatment of infantile Hemangiomas; the efficacy of laparoscopic lauromacrogol sclerotherapy in the treatment of simple hepatic cystsh (9)(10)(11)(12). Lauromacrogol has been confirmed to have a significant killing effect on liver cancer cells in in vitro experiments on liver cancer cell lines and inhibit the growth of liver cancer cells in a dose-dependent manner.…”

MicroRNA‑203a‑3p improves bleomycin and pingyangmycin sensitivity by inactivating the PI3K/AKT pathway in hemangioma

“…The first-line treatments for hemangioma include propranolol, corticosteroids, β-blockers, topical timolol and pulsed dye laser therapy (6)(7)(8). However, nearly 10-15% of patients do not respond to treatments and sclerotherapy can be offered as a subsequent treatment due to its efficacy, safety, affordability and non-invasive nature in patients with hemangioma (6,(9)(10)(11)(12)(13)(14). Bleomycin (BLM) and pingyangmycin (PYM) are drugs used in sclerotherapy that act by preventing DNA replication to interfere with cell division and proliferation (15)(16)(17).…”